Because Sig1R is a common target, some scholars have already proposed the combined use of serotonin reuptake inhibitors (SSRI) in the treatment of cardiovascular diseases to reduce its morbidity and mortality [41]. This evidence concerns the gene SIGMAR1 and cardiovascular disorder.